Background. @entity6 results from autoimmune destruction of b-cells. Insulin-producing cells (IPCs) differentiated from mesenchymal stem cells (MSCs) in @entity1 tissues decrease blood @entity413 levels and improve survival in @entity6 @entity35 . We compared the differential ability and the curative effect of IPCs from three types of @entity1 tissue to determine the ideal source of cell therapy for @entity6 . Methods. We induced MSCs from Wharton's jelly (WJ), bone marrow (BM), and surgically resected pancreatic tissue to differentiate into IPCs. The in vitro differential function of these IPCs was compared by insulin-to-DNA ratios and C-peptide levels after @entity413 challenge. In vivo curative effects of IPCs transplanted into @entity6 @entity35 were monitored by weekly blood @entity413 measurement. Results. WJ-MSCs showed better proliferation and differentiation potential than pancreatic MSCs and BM-MSCs. In vivo, WJ-IPCs significantly reduced blood @entity413 levels at first week after transplantation and maintained significant decrease till week 8. BM-IPCs reduced blood @entity413 levels at first week but gradually increased since week 3. In resected pancreas-IPCs group, blood @entity413 levels were significantly reduced till two weeks after transplantation and gradually increased since week 4. Conclusion. WJ-MSCs are the most promising stem cell source for b-cell regeneration in @entity6 treatment.

Comparisons of Differentiation Potential in XXXX Mesenchymal Stem Cells from Wharton's Jelly, Bone Marrow, and Pancreatic Tissues.

@entity1 :: ('9606', 'Species') :: ['human'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes', 'Type 1 diabetes mellitus']
@entity1 :: (9606,Species) :: ['Human']
